GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (FRA:CNB1) » Definitions » Additional Paid-In Capital

Fortress Biotech (FRA:CNB1) Additional Paid-In Capital : €674.63 Mil(As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Fortress Biotech Additional Paid-In Capital?


Fortress Biotech's quarterly additional paid-in capital declined from Sep. 2023 (€658.01 Mil) to Dec. 2023 (€657.85 Mil) but then increased from Dec. 2023 (€657.85 Mil) to Mar. 2024 (€674.63 Mil).

Fortress Biotech's annual additional paid-in capital increased from Dec. 2021 (€580.59 Mil) to Dec. 2022 (€638.09 Mil) and increased from Dec. 2022 (€638.09 Mil) to Dec. 2023 (€657.85 Mil).

Fortress Biotech Additional Paid-In Capital Historical Data

The historical data trend for Fortress Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Additional Paid-In Capital Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 415.69 479.23 580.59 638.09 657.85

Fortress Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 647.67 645.08 658.01 657.85 674.63

Fortress Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Fortress Biotech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortress Biotech (FRA:CNB1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (FRA:CNB1) » Definitions » Additional Paid-In Capital
Comparable Companies
SYBX GLTO NNVC SNSE VBIV AXLA QSAM CNTX NRBO COCP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
FBIOP.PFD:USA FBIO:USA CNB0.PFD:Germany
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Website
https://www.fortressbiotech.com
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Fortress Biotech (FRA:CNB1) Headlines

No Headlines